An in vitro study showed that TPCA-1, a substance also known as an inhibitor of NF-κB, significantly inhibited the release of CCL-2 from HeLa cells (adenocarcinoma of the cervix). The gene discussed is NFKB1; the disease is cervical adenocarcinoma.